

## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents

P.O. Box 1450

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 4 should be completed where appropriate, all further correspondence address; and indicated unless corrected below or directed otherwise in Block I, by (a) specifying a new correspondence address; and indicated unless corrected below or directed otherwise in Block I, by (a) specifying a new correspondence address; and address; and address; and address; and address; and address and addre					or <u>F</u>	Alexandria, Virgin ax (571) 273-2885	ia 22313-1450	•	
CURRENT CORRESPONDENCE ADDRESS Robe: Legibly mark-up with any corrections or use Block 1)  26 18 1 7590 11/30/2005  303/03/2006 TBESHRHE 00000058 10734552  300.00 0P  FC:2501 700.00 0P  FSISM & RICHARDSON P.C. P.O. Box 1022  Minneapolis, MN 55440-1022  Minneapolis, MN 5540-1022  MINDER MI	completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a ne							fees will be mailed to	
Interest postile part that this Feeds; 1 Transmittal is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to the Mail Stop ISSUE FEE address above on the date indicated below.    Express Mail Label No. EV 583 597 273 US	03/	CURRENT CORRESPONDENCE 26181	26181 7590 11/30/200			Note: A certificate of of the Fee(s) Transmaccompanying paper formal drawing, mustransmission.	Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.  Certificate of Express Mailing I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to the Mail Stop ISSUE FEE address above on the date indicated below.		
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10734,552 12/11/2003 Bradley G. Thompson 16596-006003 2421  TITLE OF INVENTION: METHOD OF PRODUCING INFECTIOUS REOVIRUS  APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional YES 5700 \$300 \$1000 02/28/2006  EXAMINER ART UNIT CLASS-SUBCLASS  Li, Bao Q. 1648  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).		FC: 1504 300.00 OP FISH & RICHARDSON P.C.				I hereby certify that t United States Postal addressed to the Mail			
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/734,552 12/11/2003 Bradley G. Thompson 16596-400003 2421  TITLE OF INVENTION: METHOD OF PRODUCING INFECTIOUS REOVIRUS  APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional YES \$700 \$300 \$1000 02/28/2006  EXAMINER ART UNIT CLASS-SUBCLASS  LI, Bao Q. 1648  1. Change of correspondence address or indication of "Fee Address" (37   CFR 1.363).  [] CR 1.363).  [] Change of correspondence address or indication of "Fee Address" (37   CFR 1.363).  [] CR 2. Address' indication (or "Fee Address" Indication form PITO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer PITO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer PITO/SB/47 (Sev 03-02) or more recent) attached. Use of a Customer Will be printed.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  Oncolytics Blotech Inc.  Calgary, Alberta  Please check the appropriate assignee category or categories (will not be printed on the patent). [] individual [X] corporation or other private group entity [] government  4a. The following fee(s) are enclosed:  [X] Issue Fee  [X] Publication Fee (No small entity Status indicated above.  Above The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above			55440-1022			Express Mail Lal	Express Mail Label No. EV 583 597 273 US		
TITLE OF INVENTION: METHOD OF PRODUCING INFECTIOUS REOVIRUS  APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional YES \$700 \$300 \$1000 \$2728/2006  EXAMINER ART UNIT CLASS-SUBCLASS  Li, Bao Q. 1648  1. Change of correspondence address or indication of "Fee Address" (37) [CFR 1.363).    CFR 1.363).   CFR 1.363).   The Contract of Correspondence address (or Change of Correspondence Address from PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/22) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/23) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/24) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/24) attached.     The Gardess' indication (or "Fee Address" Indication form PTO/SB/1/24) attached.     The Director of the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment has been previously submitted to the USPTO is required by the Issue Fee and Publication for the Fee(s):     The Director of the USPTO is required by the Issue Fee and Publication fee (in Capital and Publication fee (for cquired by lin not be accepted from anyone other than the applicant, a registered agent or, or the assignment or other par							02/27/2006 (Da		
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE  nonprovisional YES \$700 \$300 \$1000 02/28/2006  EXAMINER ART UNIT CLASS-SUBCLASS  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  1. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  1. ] "Fee Address" indication (or "Fee Address" Indication form PTO/SB/122) attached.  1. ] "Fee Address" indication (or "Fee Address" Indication form PTO/SB/122) attached.  2. For printing on the patent front page, list (1) the name of a single firm (having as a member a registered attorney or agents and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  Oncolytics Biotech Inc.  Calgary, Alberta  Please check the appropriate assignee category or categories (will not be printed on the patent): 1 individual [X] corporation or other private group entity [ ] government  4a. The following fee(s) are enclosed:  [X] Publication Fee (No small entity discount permitted)  [ ] Advance Order - # of Copies  [ ] Applicant claims SMALL ENTITY status. See 37 CFR 1.2.7.  [ ] B. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.2.7(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if envi) or to re-apply any previously paid issue fee to the application identified above.  NOTE: The issue Fee and Publication Fee (if envi) or to re-apply any previously paid issue fee to the application identified above.  NOTE: The issue Fee and Publication Fee (if required) will not		APPLICATION NO.	FILING DATE		FIRST NAME	D INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE nonprovisional YES \$700 \$300 \$1000 02/28/2006  EXAMINER ART UNIT CLASS-SUBCLASS  Li, Bao Q. 1648  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).    CFR 1.363).   2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents. If no name is listed, no name will be printed.    3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USP1O or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.    All Post ASSIGNEE   All Post Address   All Post		10/734,552		Bradley G.	Thompson	16596-006003	2421		
EXAMINER   ART UNIT   CLASS-SUBCLASS		TITLE OF INVENTION: METHOD OF PRODUCING INFECTIOUS REOVIRUS							
EXAMINER  ART UNIT  CLASS-SUBCLASS  1. Change of correspondence address or indication of "Fee Address" (37  CFR 1.363).  1		L				PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
Li, Bao Q.  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  1. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  1. ] "Fee Address" indication for "Fee Address" Indication form PTO/SB/122) attached.  1. ] "Fee Address" indication for "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filling an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE (CITY and STATE OR COUNTRY)  Oncolytics Biotech Inc.  Please check the appropriate assignee category or categories (will not be printed on the patent). [ ] individual [X] corporation or other private group entity [ ] government  4a. The following fee(s) are enclosed:  [X] Issue Fee  [X] Publication Fee (No small entity discount permitted)  [ ] Advance Order - # of Copies  [ N] A check in the amount of the fee(s) is enclosed.  [ X] The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 06-1050 (enclose an extra copy of this form).  5. Change in Entity Status (from status indicated above)  [ ] Ja. Applicant claims SMALL ENTITY status. See 37 CFR 1.2.7(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered agent or; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.		nonprovisional	YES	\$7	00	\$300	\$1000	02/28/2006	
Li, Bao Q.  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  1. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  1. ] "Fee Address" indication for "Fee Address" Indication form PTO/SB/122) attached.  1. ] "Fee Address" indication for "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.  3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)  PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filling an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE (CITY and STATE OR COUNTRY)  Oncolytics Biotech Inc.  Please check the appropriate assignee category or categories (will not be printed on the patent). [ ] individual [X] corporation or other private group entity [ ] government  4a. The following fee(s) are enclosed:  [X] Issue Fee  [X] Publication Fee (No small entity discount permitted)  [ ] Advance Order - # of Copies  [ N] A check in the amount of the fee(s) is enclosed.  [ X] The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 06-1050 (enclose an extra copy of this form).  5. Change in Entity Status (from status indicated above)  [ ] Ja. Applicant claims SMALL ENTITY status. See 37 CFR 1.2.7(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered agent or; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.		EXA	FXAMINER		INIT	CLASS-SUBCLASS	1		
CFR 1.363).   Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.   Correspondence Address form PTO/SB/122 attached.   Correspondence Address for Pto/SB/122 attached.   C		Li, Bao Q. 16  1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).    ] Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.    ] "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer							
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE (CITY and STATE OR COUNTRY)  Oncolytics Biotech Inc.  Calgary, Alberta  Please check the appropriate assignee category or categories (will not be printed on the patent): [ ] individual [X] corporation or other private group entity [ ] government  4a. The following fee(s) are enclosed:  [X] Issue Fee [X] Publication Fee (No small entity discount permitted)  [ ] Advance Order - # of Copies  [ X] The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 06-1050 (enclose an extra copy of this form).  5. Change in Entity Status (from status indicated above)  [ ] Ja. Applicant claims SMALL ENTITY status. See 37 CFR 1.2.7.  [ ] b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  NOTE: The issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered agent or; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.					names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name				
Please check the appropriate assignee category or categories (will not be printed on the patent): [] individual [X] corporation or other private group entity [] government  4a. The following fee(s) are enclosed: [X] Issue Fee [X] Publication Fee (No small entity discount permitted) [Advance Order - # of Copies		3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has be previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.  (A) NAME OF ASSIGNEE  (B) RESIDENCE (CITY and STATE OR COUNTRY)  Oncolytics Biotech Inc.  Calgary, Alberta							
4a. The following fee(s) are enclosed:  [X] Issue Fee [X] Publication Fee (No small entity discount permitted) [Advance Order - # of Copies									
[ ]a. Applicant claims SMALL ENTITY status. See 37 CFR 1.2.7. [ ]b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).  The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  NOTE: The issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered agent or; or the assignee or other party in interest as shown by the records of the United Party and Trademark Office.		[X] Issue Fee [X] Publication Fee (No small entity discount permitted)			<ul> <li>[X] A check in the amount of the fee(s) is enclosed.</li> <li>[ ] Payment by credit card. Form PTO-2038 is attached.</li> <li>[X] The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to</li> </ul>				
The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.  NOTE: The issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered agent or; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.		· · · · · · · · · · · · · · · · · · ·							
(Authorized Signature) (Date) February 27, 2006									
			1, 6						

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Registration No. 54,961

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Typed or Printed Name Kraig K. Anderson